Piper Jaffray Companies set a $208.00 price objective on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report issued on Wednesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Other equities analysts have also recently issued reports about the company. Stifel Nicolaus raised their price objective on Jazz Pharmaceuticals from $180.00 to $205.00 and gave the stock a buy rating in a research note on Wednesday, August 8th. BMO Capital Markets raised their price objective on Jazz Pharmaceuticals from $201.00 to $206.00 and gave the stock an outperform rating in a research note on Wednesday, August 8th. Zacks Investment Research cut Jazz Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 10th. Citigroup raised their price objective on Jazz Pharmaceuticals from $162.00 to $205.00 and gave the stock a buy rating in a research note on Tuesday, July 10th. Finally, BidaskClub upgraded Jazz Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, July 24th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $190.61.
Shares of JAZZ stock traded up $1.78 during mid-day trading on Wednesday, reaching $142.19. 1,743,725 shares of the company were exchanged, compared to its average volume of 498,591. Jazz Pharmaceuticals has a fifty-two week low of $130.15 and a fifty-two week high of $184.00. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $9.93 billion, a P/E ratio of 14.87, a PEG ratio of 0.89 and a beta of 1.06.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,300 shares of the firm’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $159.45, for a total value of $207,285.00. Following the sale, the chief executive officer now directly owns 278,615 shares in the company, valued at $44,425,161.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $158.08, for a total value of $110,656.00. Following the completion of the sale, the chief financial officer now owns 32,768 shares in the company, valued at $5,179,965.44. The disclosure for this sale can be found here. Insiders sold 34,678 shares of company stock worth $5,959,173 over the last quarter. 3.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of JAZZ. Stratos Wealth Partners LTD. bought a new stake in Jazz Pharmaceuticals in the third quarter valued at $106,000. Tiverton Asset Management LLC bought a new stake in Jazz Pharmaceuticals in the second quarter valued at $198,000. Moloney Securities Asset Management LLC bought a new stake in Jazz Pharmaceuticals in the second quarter valued at $204,000. FDx Advisors Inc. bought a new stake in Jazz Pharmaceuticals in the second quarter valued at $244,000. Finally, Cadence Capital Management LLC bought a new stake in Jazz Pharmaceuticals in the third quarter valued at $263,000. Institutional investors own 92.95% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Read More: Treasury Bonds
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.